(Q41719217)

8 October 2017

1 reference

title

A practical approach to diagnosis and management of Gaucher's disease (English)

1 reference

8 October 2017

1 reference

Mistry PK

1

1 reference

PubMed ID

9497866

8 October 2017

Abrahamov A

series ordinal

2

1 reference

8 October 2017

1 December 1997

1 reference

Best Practice and Research: Clinical Haematology

8 October 2017

1 reference

8 October 2017

10

1 reference

8 October 2017

4

1 reference

8 October 2017

817-838

1 reference

Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype

8 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

To affinity ... and beyond!

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

1 reference

7 January 2021

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Enzyme replacement treatment in type 1 and type 3 Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Detection of the defect of Gaucher's disease and its carrier state in peripheral-blood leucocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Gaucher disease mutations in non-Jewish patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Alglucerase for Gaucher's disease: dose, costs and benefits

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Erroneous assignment of Gaucher disease genotype as a consequence of a complete gene deletion

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

The facile detection of the nt 1226 mutation of glucocerebrosidase by 'mismatched' PCR.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Acid hydrolases in leukocytes and platelets of normal subjects and in patients with Gaucher's and Fabry's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Pathological findings in Gaucher disease type 2 patients following enzyme therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

The role of neurogenetics in Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Frequency of pseudo-Gaucher cells in diagnostic bone marrow biopsies from patients with Ph-positive chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Orthotopic liver transplantation in the treatment of complications of type 1 Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

HCG contamination of alglucerase: clinical implications in low-dose regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease: comparison to computed tomographic measurements

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

A less costly regimen of alglucerase to treat Gaucher's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

A 27-year experience with splenectomy for Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Comparison of magnetic resonance imaging and ultrasound in evaluating liver size in Gaucher patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Current issues in enzyme therapy for Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Pulmonary hypertension in two patients with type I Gaucher disease while on alglucerase therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Individualised low-dose alglucerase therapy for type 1 Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Genotype/phenotype correlations in Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Genetic diagnosis of Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Glucocerebrosidase treatment of type I Gaucher disease with severe pulmonary involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

DNA mutational analysis of type 1 and type 3 Gaucher patients: how well do mutations predict phenotype?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Gaucher's disease in the United Kingdom: screening non-Jewish patients for the two common mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Prediction of severity of Gaucher's disease by identification of mutations at DNA level

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Enzyme replacement therapy in type 1 and type 3 Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Outcome of partial splenectomy for type I Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

Replacement therapy with imiglucerase for type 1 Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2897%2980042-X

7 January 2021

10.1016/S0950-3536(97)80042-X

Identifiers

DOI

1 reference

8 October 2017

1 reference

PubMed ID

9497866